Press Release - Company Data

Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Posted 2013-05-02 07:09NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for th

Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
Posted 2013-03-14 06:34NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Step

Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary
Posted 2013-03-12 00:33NAI Editing
announced today that the Department of Veterans Affairs has made OFIRMEV®(acetaminophen) injection available on the VA National Formulary (VANF).

Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Posted 2013-03-07 01:13NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for th

Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection
Posted 2013-03-06 13:09NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement

Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
Posted 2013-01-23 00:25NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a preliminary (unaudite

Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
Posted 2012-12-12 00:34NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that it has entered int

Cadence Pharmaceuticals Announces Settlement of OFIRMEV® (Acetaminophen) Injection Patent Litigation with Perrigo Company
Posted 2012-11-28 00:00NAI Editing
today announced that it has entered into settlement and license agreements with Perrigo Company (Nasdaq: PRGO; TASE), and its subsidiary, Paddock Laboratories, LLC, to resolve pending patent litigatio

Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
Posted 2012-11-05 11:44NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for th

Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
Posted 2012-08-02 07:01NAI Editing
a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for th